REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)

Corporate News

JAPAN, June 24, 2026 – REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in patients with…

AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy

Blogs

Induced pluripotent stem cells (iPSCs) are rapidly advancing regenerative medicine and cell therapy because they can differentiate into multiple human cell types. However, immune rejection remains a major barrier to developing scalable allogeneic cell therapies. In a recent webinar, Dr. Luke Ren from REPROCELL presented how the company is using StemEdit, its advanced gene editing…